Published July 25, 2023
| Version v1
Dataset
Open
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial
Contributors
Project members:
- Bharat Burman1
- Swati Jain1
- Conall W.R. Fitzgerald1
- Eric J. Sherman1
- Lara A. Dunn1
- James V. Fetten1
- Loren S. Michel1
- Anuja Kriplani1
- Kenneth K. Ng1
- Juliana Eng1
- Vatche Tchekmedyian2
- Sofia Haque1
- Nora Katabi1
- Fengshen Kuo1
- Catherine Y. Han1
- Zaineb Nadeem1
- Wei Yang1
- Vladimir Makarov3
- Raghvendra M. Srivastava3
- Irina Ostrovnaya1
- Manu Prasad1
- Charlotte L. Zuur4
- Nadeem Riaz1
- David G. Pfister1
- Christopher A. Klebanoff1
- Timothy A. Chan3
Supervisors:
- 1. Memorial Sloan Kettering Cancer Center
- 2. Maine Medical Center-Tufts University School of Medicine
- 3. Cleveland Clinic
- 4. The Netherlands Cancer Institute – Antoni van Leeuwenhoek Hospital
Description
This is a de-identified dataset accompanying the Nature Medicine publication titled "Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial", by Vos et al. (DOI: https://doi.org/10.1038/s41591-023-02518-x). It contains the clinical features and processed data of 64 patients with salivary gland cancer, treated with nivolumab and ipilimumab immunotherapy. These data underlie results reported in the article. Raw whole-exome and RNA sequencing data generated in this study have been made publicly available at SRA under BioProject number PRJNA940989.
Files
Files
(59.8 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:aaed381e01c02fe393b9b19a96b2e2b9
|
59.8 kB | Download |